XOMA Corporation Stock News

Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has cl...

EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March.  Management will also participate in one-on-one investor meetings.

EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually, February 11-12, 2025.

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.

Zevra's MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio

XOMA Royalty has acquired 50 percent of Twist's existing royalty and milestone economics for $15 million XOMA Royalty's portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetiza...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator. Under the terms of the agreement, XOMA Royal...

XOMA Royalty Corporation offers diversified revenue streams from milestone and royalty rights in various therapeutic areas, providing stable returns with lower clinical trial risks. The company's preferred shares, XOMAP and XOMAO, offer high, reliable dividends, making them attractive for income investors seeking biotech exposure. XOMA's robust financials, including substantial cash reserves an...